Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through bone marrow or stem cell transplants, has responded well to the treatment, with more than 70 percent of participants having a partial or complete response.
The Multiple Myeloma Research Foundation will be pumping $15 million into a cancer immunotherapy initiative over the next three years. The effort will start with the foundation asking immuno-oncology experts, pharmaceutical industry leaders, and government healthcare officials to identify areas of greatest need. The initiative itself will be divided into two phases: a…
The U.S. Food and Drug Administration (FDA) has ordered Merck to suspend two Phase 3 and part of a Phase 1 clinical trials in which Keytruda (pembrolizumab) is tested in combination with the drugs Pomalyst (pomalidomide) or Revlimid (lenalidomide) for multiple myeloma.
The U.S. Food and Drug Administration (FDA) recently approved a lab test to aid in the detection and diagnosis of myeloma and a range of other blood cancers. The ClearLLab Reagents test now becomes the first FDA-authorized assessment for use with a method called flow cytometry to detect blood cancers, including…
Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3 ELOQUENT-2 trial (NCT01239797) after four years of follow-up, Bristol-Myers Squibb announced. After the four-year period, 21 percent of patients were still alive and…
Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according to long-term follow-up data of two Phase 1/2 trials presented at the 2017 European Hematology Association annual meeting, held June 22-25 in Madrid, Spain. Takeda‘s…
Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this fate, Wright began running marathons. Last November, at age 75, he reached his goal of running 100 marathons with cancer. Now he’s trying to qualify for…
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva (denosumab) to include patients with multiple myeloma, the biotechnology company Amgen announced. Xgeva is indicated for the prevention of fractures, spinal cord compression, or…
The U.S. Federal Drug Administration has approved a combination of the immunotherapies Darzalex (daratumumab), Pomalyst (pomalidomide) and dexamethasone as a multiple myeloma treatment, according to Darzalex’s developer, Janssen Biotech. The combo offers a new option for patients who fail to respond to two lines of therapy that include Revlimib (lenalidomide) and…
Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners will use Dragonfly’s TriNKET immunotherapy platform, which is based on Natural Killer (NK) cells. Under the agreement, Dragonfly will receive $33 million up-front to develop blood-cancer treatments, while Celgene will obtain…
Get regular updates to your inbox.